Minimal information is available regarding antiretroviral prescribing patterns and outcomes for HIV patients in correctional systems. This study analyzes single- (STR) and multiple- (MTR) tablet regimen effectiveness in patients receiving HIV telemedicine care through the Illinois Department of Corrections (IDOC). This study involves a retrospective review of HIV-positive adult patients in IDOC on either an STR (efavirenz, rilpivirine, elvitegravir based) or an MTR (emtricitabine/tenofovir with atazanavir/ritonavir, darunavir/ritonavir, or raltegravir). No significant differences in virologic suppression were seen between groups at baseline, weeks 24, 48, 96, and last clinic visit. Similar proportions of patient-reported adverse effects, self-reported adherence, and discontinuation rates were found in both groups. With similar rates of viral suppression, tolerability, adherence, and discontinuation, administering MTR in the incarcerated population is a viable alternative to STR.
AidalaA. A., LeeG., AbramsonD. M., MesseriP., SieglerA. (2007). Housing need, housing assistance, and connection to HIV medical care. AIDS and Behavior, 11, 101–115.
2.
Al-DakkakI., PatelS., McCannE., GadkariA., PrajapatiG., MaieseE. M. (2013). The impact of specific HIV treatment-related adverse events on adherence to antiretroviral therapy: A systematic review and meta-analysis. AIDS Care, 25, 400–414.
3.
AlticeF. L., MostashariF., FriedlandG. H. (2001). Trust and the acceptance of antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 28, 47–58.
4.
AndersenM., HockmanE., SmereckG., TinsleyJ., MilfortD., WilcoxR.…ThomasR. (2007). Retaining women in HIV medical care. Journal of the Association of Nurses in AIDS Care, 18, 33–41.
5.
BangsbergD. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939–941.
6.
BlackwelderW. C. (1982). “Proving the null hypothesis” in clinical trials. Controlled Clinical Trials, 3, 345–353.
ChiampasT. D., KimH., BadowskiM. (2015). Evaluation of the occurrence and type of antiretroviral and opportunistic infection medication errors within the inpatient setting. Pharmacy Practice, 13, 512–518.
9.
DasM., ChuP. L., SantosG. M., ScheerS., VittinghoffE., McFarlandW., ColfaxG. N. (2010). Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One, 5, e11068.
10.
DeJesusE., RockstrohJ. K., HenryK., MolinaJ. M., GatheJ., RamanathanS.…GS-236-0103 Study Team. (2012). Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: A randomised, double-blind, phase 3, non-inferiority trial. Lancet, 379, 2429–2438.
11.
DeJesusE., YoungB., Morales-RamirezJ. O., SloanL., WardD. J., FlahertyJ. F.…AI266073 Study Group. (2009). Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients. Journal of Acquired Immune Deficiency Syndromes, 51, 163–174.
12.
GardnerE. M., McLeesM. P., SteinerJ. F., Del RioC., BurmanW. J. (2011). The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clinical Infectious Diseases, 52, 793–800.
13.
GillV. S., LimaV. D., ZhangW., WynhovenB., YipB., HoggR. S.…HarriganP. R. (2010). Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. Clinical Infectious Diseases, 50, 98–105.
14.
MaruschakL. M. (2015). HIV in prisons 2001-2010 (NCJ 238877). Washington, DC: Bureau of Justice Statistics.
15.
MeyerJ. P., CepedaJ., WuJ., TrestmanR. L., AlticeF. L., SpringerS. A. (2014). Optimization of human immunodeficiency virus treatment during incarceration: Viral suppression at the prison gate. JAMA Internal Medicine, 174, 721–729.
16.
Panel on Antiretroviral Guidelines for Adults and Adolescents. (2016). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services. Retrieved from http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf
17.
PulsR. L., SrasuebkulP., PetoumenosK., BoeseckeC., DuncombeC., BellosoW. H.…Altair Study Group. (2010). Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: Week 48 data from the Altair study. Clinical Infectious Diseases, 51, 855–864.
18.
RamjanR., CalmyA., VitoriaM., MillsE. J., HillA., CookeG., FordN. (2014). Systematic review and meta-analysis: Patient and programme impact of fixed-dose combination antiretroviral therapy. Tropical Medicine & International Health, 19, 501–513.
19.
SaberiP., DongB. J., JohnsonM. O., GreenblattR. M., CocohobaJ. M. (2012). The impact of HIV clinical pharmacists on HIV treatment outcomes: A systematic review. Patient Preference and Adherence, 6, 297–322.
20.
SaxP. E., MeyersJ. L., MugaveroM., DavisD. L. (2012). Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One, 7, e31591.
21.
TobiasC. R., CunninghamW., CabralH. D., CunninghamC. O., EldredL., Naar-KingS.…DrainoniM. L. (2007). Living with HIV but without medical care: Barriers to engagement. AIDS Patient Care and STDS, 21, 426–434.
22.
UlettK. B., WilligJ. H., LinH. Y., RoutmanJ. S., AbromsS., AllisonJ.…MugaveroM. J. (2009). The therapeutic implications of timely linkage and early retention in HIV care. AIDS Patient Care and STDS, 23, 41–49.
23.
WallenskyR. P., SaxP. E., NakamuraY. M., WeinsteinM. C., PeiP. P., FreedbergK. A.…SchackmanB. R. (2013). Economic savings versus health losses: The cost-effectiveness of generic antiretroviral therapy in the United States. Annals of Internal Medicine, 158, 84–92.
24.
WilliamsB., AmicoK. R., Konkle-ParkerD. (2011). Qualitative assessment of barriers and facilitators to HIV treatment. Journal of the Association of Nurses in AIDS Care, 22, 307–312.
25.
WohlD. A., StephensonB. L., GolinC. E., KiziahC. N., RosenD., NgoB.…KaplanA. H. (2003). Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Clinical Infectious Diseases, 36, 1572–1576.
26.
YoungJ., PatelM., BadowskiM., Mackesy-AmitiM. E., VaughnP., ShickerL.…OuelletL. J. (2014). Improved virologic suppression with HIV subspecialty care in a large prison system using telemedicine: An observational study with historical controls. Clinical Infectious Diseases, 59, 123–126.
27.
ZallerN., ThurmondP., RichJ. D. (2007). Limited spending: An analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners. Public Health Reports, 122, 49–54.
